Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
| Published in: | Journal for ImmunoTherapy of Cancer |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Online Access: | https://jitc.bmj.com/content/13/3/e011909.full |